-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UGxYj2EC0cOY3Ty27ikx87mtwo46bUXCLG/+cXTYyTb1H8hBKZLBHPKiHTJLG5+T
 5C120EqZOV18wKkwK7pzoQ==

<SEC-DOCUMENT>0001209191-09-042994.txt : 20090902
<SEC-HEADER>0001209191-09-042994.hdr.sgml : 20090902
<ACCEPTANCE-DATETIME>20090902163340
ACCESSION NUMBER:		0001209191-09-042994
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090831
FILED AS OF DATE:		20090902
DATE AS OF CHANGE:		20090902

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Schroeder Theodore R
		CENTRAL INDEX KEY:			0001378690

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33103
		FILM NUMBER:		091051257

	MAIL ADDRESS:	
		STREET 1:		12481 HIGH BLUFF DRIVE, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CADENCE PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001333248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		12481 HIGH BLUFF DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		8584361400

	MAIL ADDRESS:	
		STREET 1:		12481 HIGH BLUFF DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-08-31</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001333248</issuerCik>
        <issuerName>CADENCE PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>CADX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001378690</rptOwnerCik>
            <rptOwnerName>Schroeder Theodore R</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CADENCE PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>12481 HIGH BLUFF DRIVE, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92130</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President, CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted stock units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2009-08-31</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>40000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>40000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each restricted stock unit represents a contingent right to
receive one share of the Company's common stock.</footnote>
        <footnote id="F2">1/2 of the shares subject to the restricted stock unit award vest and convert into shares of common stock on the earlier of (a) FDA approval of the Company's NDA for intravenous acetaminophen if such approval is obtained before December 31, 2009, and (b) immediately prior to the consummation of a change in control of the Company if such change in control occurs before December 31, 2009. Subject to the recipient's election to defer the receipt of common stock subject to the other 1/2 of the shares subject to the restricted stock unit award, such shares vest and convert into shares of common stock on the earlier of (a) the one-year anniversary of FDA approval of the Company's NDA for intravenous acetaminophen, and (b) immediately prior to the consummation of a change in control of the Company. In each case, vesting is subject to the recipient's continued status as an employee, independent director or consultant of the Company or any subsidiary on the applicable vesting date.</footnote
>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>Hazel M. Aker
Attorney-in-fact</signatureName>
        <signatureDate>2009-09-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----